Buffalo News reports UB spinoff sells rights to potential muscular dystrophy treatment

Published October 8, 2014 This content is archived.

An article in the Buffalo News reports Tonus Therapeutics, a Buffalo biotech startup company that was spun off from research conducted at UB and is pursuing a treatment for a form of muscular dystrophy based on a protein found in tarantula venom, has sold the rights to the drug to Akashi Therapeutics, a Cambridge, Mass., clinical stage biopharmaceutical firm.

http://www.buffalonews.com/business/buffalo-biotech-startup-sells-rights-to-potential-muscular-dystrophy-treatment-20141008